85 results
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
7 May 24
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
7:09am
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation
S-3ASR
EX-1.2
BEAM
Beam Therapeutics Inc
27 Feb 24
Automatic shelf registration
6:10pm
law or otherwise (including in settlement of any litigation), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof … of foreign jurisdictions where Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation), arises out
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
27 Feb 24
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
6:43am
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
8 Jan 24
Results of Operations and Financial Condition
6:55am
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include
8-K
EX-99.2
rbz20vn 8ux
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
kxol0 cm81euuwyl9npg
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
EX-99.1
9zvozqq64 1w
14 Dec 23
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
4:05pm
8-K
EX-99.1
l0i1cxd4234mjf z1rym
8 Nov 23
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
7:00am
8-K
EX-99.1
f7o ts96z37v
31 Oct 23
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
6:44am
8-K
EX-99.1
9k1k92nxe50df0h 1hh
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
EX-99.2
038cogxug7k xbze
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
13bwirhogo7 v9yih9
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
8-K
EX-99.1
aqvqzu
8 Aug 23
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
7:11am
424B5
qhfk5obh 6mkiwbuho
10 May 23
Prospectus supplement for primary offering
5:10pm
8-K
EX-99.1
4blama
10 May 23
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
7:00am